Susquehanna Fundamental Investments LLC Takes Position in Cabaletta Bio, Inc. $CABA

Susquehanna Fundamental Investments LLC acquired a new stake in Cabaletta Bio, Inc. (NASDAQ:CABA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 152,964 shares of the company’s stock, valued at approximately $476,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Kestra Advisory Services LLC bought a new position in Cabaletta Bio during the 1st quarter worth about $32,000. SummitTX Capital L.P. purchased a new position in Cabaletta Bio during the 1st quarter valued at about $34,000. Legal & General Group Plc bought a new stake in shares of Cabaletta Bio in the 2nd quarter valued at about $34,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Cabaletta Bio in the 4th quarter valued at about $38,000. Finally, Clear Harbor Asset Management LLC purchased a new stake in shares of Cabaletta Bio in the 4th quarter worth approximately $43,000.

Cabaletta Bio Stock Performance

CABA stock opened at $3.57 on Thursday. Cabaletta Bio, Inc. has a one year low of $1.44 and a one year high of $4.23. The firm has a market cap of $605.26 million, a price-to-earnings ratio of -2.27 and a beta of 3.27. The firm has a 50-day simple moving average of $2.93 and a two-hundred day simple moving average of $3.11.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. As a group, equities analysts predict that Cabaletta Bio, Inc. will post -1.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CABA has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Cabaletta Bio in a research note on Tuesday. Jefferies Financial Group reissued a “buy” rating on shares of Cabaletta Bio in a research note on Wednesday, June 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a report on Friday, July 17th. TD Cowen raised Cabaletta Bio to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Wall Street Zen downgraded Cabaletta Bio from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.33.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.